Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Catechol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.83 |
| ▸ | CA2 | P00918 | 5/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | HPGD | P15428 | 3/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.83 |
| ▸ | CA4 | P22748 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | EGFR | P00533 | 2/20 | 0.83 |
| ▸ | FYN | P06241 | 2/20 | 0.83 |
| ▸ | MMP9 | P14780 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.83 |
| ▸ | NPC1 | O15118 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | CA12 | O43570 | 2/20 | 0.83 |
| ▸ | CA3 | P07451 | 2/20 | 0.83 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.83 |
| ▸ | RAB9A | P51151 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Catechol SCHEMBL27577771 | 0.96 | — | — | |
| Catechol SCHEMBL194225 | 0.96 | — | — | |
| Catechol SCHEMBL11041074 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2TDP1ALOX15LMNA | |
| Catechol SCHEMBL9187087 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2TDP1ALOX15LMNA | |
| Catechol SCHEMBL50719 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2TDP1ALOX15LMNA | |
| Catechol SCHEMBL27367358 | 0.92 | ALDH1A1 (0.83) | ALDH1A1CA2TDP1ALOX15LMNA | |
| Catechol SCHEMBL30088487 | 0.91 | — | — | |
| Catechol SCHEMBL11672589 | 0.91 | ALDH1A1 (1.00) | ALDH1A1CA2TDP1ALOX15LMNA | |
| Catechol SCHEMBL30944695 | 0.91 | ALDH1A1 (1.00) | ALDH1A1CA2TDP1ALOX15LMNA | |
| Catechol SCHEMBL29352716 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041302-A | Method for preparing flavonoid compound containing hydroxyl substituent | 泉州海创医药科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20250138426-A1 | SILICON-CONTAINING MOLECULAR GLASS PHOTORESIST COMPOUND WITH HIGH ETCHING RESISTANCE, PREPARATION METHOD THEREFOR, AND USE THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-05-01 | — | — | US | disclosed |
| US-20240409519-A1 | HYDROGENATED QUINOXALINES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-12 | — | — | US | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024087158-A1 | HIGH-ETCHING-RESISTANCE SILICON-CONTAINING MOLECULAR GLASS PHOTORESIST COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院化学研究所 | 2024-05-02 | — | — | WO | disclosed |
| CN-117946151-A | Silicon-containing high-etching-resistance molecular glass photoresist compound and preparation method and application thereof | 中国科学院化学研究所 | 2024-04-30 | — | — | CN | disclosed |
| CN-117616013-A | Hydrogenated quinoxalines | 大塚制药株式会社 | 2024-02-27 | — | — | CN | disclosed |
| CN-116041302-A | Method for preparing flavonoid compound containing hydroxyl substituent | 泉州海创医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023286768-A1 | HYDROGENATED QUINOXALINES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | WO | disclosed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| EP-1569939-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| CN-1620457-A | tetracyclic heterocyclic compounds as estrogen receptor modulators | ORTHO MCNEIL PHARM INC (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | HU, LONGQIN | 2004-10-28 | — | — | US | disclosed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004050660-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-0860421-A1 | PROCESS FOR PRODUCING CYCLIC UNSATURATED ALDEHYDES | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1998-08-26 | — | — | EP | disclosed |
| US-5101077-A | Allylic Alcohol, Conjugated Diene, Group 8 Metal Complex Catalyst | SHELL OIL COMPANY (US) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409519-A1 | HYDROGENATED QUINOXALINES | SLC6A3, SLC6A2, SLC18A2 | ALDH1A1 550/4885CA2 2693/4885TDP1 675/4885 |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | ALDH1A1 2801/4885CA2 776/4885TDP1 3744/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | ALDH1A1 2801/4885CA2 776/4885TDP1 3744/4885 |
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | MKI67, NME2, NTPCR | ALDH1A1 2164/4885CA2 1585/4885TDP1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.